Skip to content

Aquestive Therapeutics

US · AQST #3650 by market cap Listed 2018
4.62 0.00 -0.02%
Live - 5344 symbols - heartbeat 26s ago · 2026-10-08 10:11
Pre-market 4.50 -2.60%
After-hours 4.62 0.00%
Market cap
579.74M
P/B
-10.24
EPS
-0.78
Reader sentiment Are you bullish or bearish on AQST?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/3/2
  • Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
    TipRanks · 2026/6/26
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Aquestive Therapeutics (AQST) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
    TipRanks · 2026/2/2
  • Rating change
    A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $9
    Market Newswire · 2026/3/6
  • Rating change
    A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/5/15
  • Rating change
    Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $8
    Market Newswire · 2026/3/9
  • Rating change
    Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/6/25
  • Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6
    Market Newswire · 2026/9/17
  • LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/9/17
  • Rating change
    Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $9
    Market Newswire · 2026/3/6
  • Rating change
    Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $8
    Market Newswire · 2026/1/14
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT)
    TipRanks · 2026/5/15
  • Rating change
    A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9
    Market Newswire · 2026/5/16
  • Rating change
    Piper Sandler Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/5/15
  • Rating change
    LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
    Market Newswire · 2026/6/26
  • Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2026/6/26
  • Rating change
    Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/1/9
  • H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/9/22
  • Rating change
    LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/8/11
  • Rating change
    A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $8 to $12
    Market Newswire · 2026/2/3

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 10:11:28 · For reference only, not investment advice and not tailored to your situation.